E Ramsay Camp
Overview
Explore the profile of E Ramsay Camp including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
1280
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gao Z, Azar J, Erstad D, Sun Z, Janakiraman H, Chung D, et al.
J Surg Res
. 2025 Feb;
307:21-32.
PMID: 39970547
Introduction: Racial differences in antitumoral immunity have been identified in a variety of cancers and may contribute to survival disparities, but limited data exist exploring the molecular differences in pancreatic...
2.
Janakiraman H, Gao Z, Zhu Y, Dong J, Becker S, Janneh A, et al.
World J Oncol
. 2024 Sep;
15(5):744-757.
PMID: 39328328
Background: Epithelial-to-mesenchymal transition (EMT), cancer stem cells (CSCs), and colorectal cancer (CRC) therapy resistance are closely associated. Prior reports have demonstrated that sphingosine-1-phosphate (S1P) supports stem cells and maintains the...
3.
da Costa Jr. W, Tan M, Camp E, Thrift A
J Surg Oncol
. 2024 May;
129(8):1542-1553.
PMID: 38752435
Background: Disparities in gastric cancer (GC) outcomes show a higher disease burden among minorities. We aimed to evaluate the associations between sociodemographic and system-level factors and guideline-concordant treatment among GC...
4.
Gao Z, Azar J, Zhu H, Williams-Perez S, Kang S, Marginean C, et al.
Front Immunol
. 2024 Feb;
15:1324093.
PMID: 38361928
Pancreatic adenocarcinoma (PDAC) is an aggressive tumor with poor survival and limited treatment options. PDAC resistance to immunotherapeutic strategies is multifactorial, but partially owed to an immunosuppressive tumor immune microenvironment...
5.
Gao Z, Kang S, Erstad D, Azar J, Van Buren G, Fisher W, et al.
Front Oncol
. 2023 Dec;
13:1274783.
PMID: 38074633
Introduction: Pancreatic adenocarcinoma (PDAC) is an aggressive tumor with limited response to both chemotherapy and immunotherapy. Pre-treatment tumor features within the tumor immune microenvironment (TiME) may influence treatment response. We...
6.
Manisundaram N, Portuondo J, Erstad D, Silberfein E, Hsu C, Barakat O, et al.
J Am Coll Surg
. 2023 Feb;
236(4):861-870.
PMID: 36728341
Background: Pancreatobiliary (PB) disorders, especially cancer, negatively affect patients' health-related quality of life (HRQoL). However, the influence of baseline, preintervention HRQoL on perioperative and oncologic outcomes has not been well...
7.
da Costa Jr. W, Camp E, Thrift A
JCO Oncol Pract
. 2022 Apr;
18(7):e1181-e1197.
PMID: 35436147
Purpose: Evidence on health disparities among patients treated with multimodality therapy protocols is still limited. We aimed to evaluate the associations between patient-level and system-level factors and the receipt of...
8.
Mickel T, Kutlu O, Silberfein E, Hsu C, Chai C, Fisher W, et al.
Am J Surg
. 2022 Mar;
224(1 Pt B):635-640.
PMID: 35249728
Background: Return to Intended Oncologic Treatment (RIOT) has been proposed as a quality metric in the care of cancer patients. We sought to define factors associated with inability to RIOT...
9.
Garcia D, Siegel J, Mahvi D, Zhang B, Mahvi D, Camp E, et al.
Clin Oncol Res
. 2021 Jun;
3(6):1-11.
PMID: 34142081
Background: The impact of the COVID-19 pandemic has spread beyond those infected with SARS-CoV-2. Its widespread consequences have affected cancer patients whose surgeries may be delayed in order to minimize...
10.
Skochdopole A, Kutlu O, Engelhardt K, Lancaster W, Abbott A, Camp E
J Surg Res
. 2021 May;
263:289.
PMID: 34053695
No abstract available.